Staging of Liver Disease. Which Option is Right for My Patient?

Harjit Bhogal, Richard K. Sterling

Research output: Contribution to journalArticle

Abstract

It is important to assess the stage of liver fibrosis in chronic hepatitis C to guide treatment decisions. Liver biopsy has limitations in staging fibrosis. Several blood tests, algorithms, and imaging tests have been studied as noninvasive markers to stage fibrosis in hepatitis C. In patients without suspicion for cirrhosis, 2 noninvasive methods can be used to predict presence of absence of significant liver fibrosis; however, liver biopsy remains the gold standard. It is imperative not to miss the diagnosis of cirrhosis, because this has further implications for screening of hepatocellular carcinoma and varices.

Original languageEnglish (US)
Pages (from-to)850-861
Number of pages12
JournalInfectious Disease Clinics of North America
Volume26
Issue number4
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Patient Rights
Liver Diseases
Fibrosis
Liver Cirrhosis
Biopsy
Liver
Varicose Veins
Hematologic Tests
Chronic Hepatitis C
Hepatitis C
Hepatocellular Carcinoma
Therapeutics

Keywords

  • Hepatitis C
  • Liver fibrosis
  • Noninvasive staging

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Staging of Liver Disease. Which Option is Right for My Patient? / Bhogal, Harjit; Sterling, Richard K.

In: Infectious Disease Clinics of North America, Vol. 26, No. 4, 12.2012, p. 850-861.

Research output: Contribution to journalArticle

Bhogal, Harjit ; Sterling, Richard K. / Staging of Liver Disease. Which Option is Right for My Patient?. In: Infectious Disease Clinics of North America. 2012 ; Vol. 26, No. 4. pp. 850-861.
@article{0136a6bc16ee468981ac177a4df560f2,
title = "Staging of Liver Disease. Which Option is Right for My Patient?",
abstract = "It is important to assess the stage of liver fibrosis in chronic hepatitis C to guide treatment decisions. Liver biopsy has limitations in staging fibrosis. Several blood tests, algorithms, and imaging tests have been studied as noninvasive markers to stage fibrosis in hepatitis C. In patients without suspicion for cirrhosis, 2 noninvasive methods can be used to predict presence of absence of significant liver fibrosis; however, liver biopsy remains the gold standard. It is imperative not to miss the diagnosis of cirrhosis, because this has further implications for screening of hepatocellular carcinoma and varices.",
keywords = "Hepatitis C, Liver fibrosis, Noninvasive staging",
author = "Harjit Bhogal and Sterling, {Richard K.}",
year = "2012",
month = "12",
doi = "10.1016/j.idc.2012.08.002",
language = "English (US)",
volume = "26",
pages = "850--861",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Staging of Liver Disease. Which Option is Right for My Patient?

AU - Bhogal, Harjit

AU - Sterling, Richard K.

PY - 2012/12

Y1 - 2012/12

N2 - It is important to assess the stage of liver fibrosis in chronic hepatitis C to guide treatment decisions. Liver biopsy has limitations in staging fibrosis. Several blood tests, algorithms, and imaging tests have been studied as noninvasive markers to stage fibrosis in hepatitis C. In patients without suspicion for cirrhosis, 2 noninvasive methods can be used to predict presence of absence of significant liver fibrosis; however, liver biopsy remains the gold standard. It is imperative not to miss the diagnosis of cirrhosis, because this has further implications for screening of hepatocellular carcinoma and varices.

AB - It is important to assess the stage of liver fibrosis in chronic hepatitis C to guide treatment decisions. Liver biopsy has limitations in staging fibrosis. Several blood tests, algorithms, and imaging tests have been studied as noninvasive markers to stage fibrosis in hepatitis C. In patients without suspicion for cirrhosis, 2 noninvasive methods can be used to predict presence of absence of significant liver fibrosis; however, liver biopsy remains the gold standard. It is imperative not to miss the diagnosis of cirrhosis, because this has further implications for screening of hepatocellular carcinoma and varices.

KW - Hepatitis C

KW - Liver fibrosis

KW - Noninvasive staging

UR - http://www.scopus.com/inward/record.url?scp=84867662796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867662796&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2012.08.002

DO - 10.1016/j.idc.2012.08.002

M3 - Article

C2 - 23083819

AN - SCOPUS:84867662796

VL - 26

SP - 850

EP - 861

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 4

ER -